Cambridge, MA – Aug 14, 2025 – Insilico Medicine(“Insilico”), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has completed IND-enabling studies with favorable results. Insilico plans to submit IND application in Q4 this year, aiming to progress the candidate compound into clinical trials as a potential transformative therapy for Parkinson’s disease (PD).

Every human being leaves traces behind, and has done so for thousands of years. In a new study, a team led by lead author Dr. Yanming Ruan from MARUM – Center for Marine Environmental Sciences at the University of Bremen shows that human influence on soil erosion goes back much further than previously thought. Their findings have now been published in Geophysical Research Letters.

Relocatable modular buildings (RMBs) represent a sustainable construction method where buildings are assembled and transported easily using prefabricated modules. However, challenges in management and logistics hinder their wider adoption. In a new study, researchers developed an innovative digital twin facility management system tailored specifically for RMBs. This advanced framework integrates cutting-edge technologies to enhance management efficiency throughout the building lifecycle, establishing a foundation for wider digital twin integration in construction.